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ABSTRACT: Thework presented herewasmotivated by the premise that the amorphous
state serves as amediumto study cocrystal formation.Themolecularmobility inherent to
amorphous phases can lead tomolecular associations betweendifferent components such
that a single crystalline phase of multiple components or cocrystal is formed.
Cocrystallization pathways and kinetics were investigated from amorphous equimolar
phases of carbamazepine and nicotinamide using hot-stage polarized microscopy
(HSPM), hot-stage Raman microscopy (HSRM), differential scanning calorimetry
(DSC), and X-ray powder diffraction (XRPD). Nonisothermal studies revealed that
amorphous phases generate cocrystals and that thermal history affects crystallization
pathways in significant ways. Two different pathways to cocrystal formation from
the amorphous phase were identified: (1) at low heating rates (38C/min) a metastable
cocrystalline phase initially nucleates and transforms to the more stable cocrystalline
phase of CBZ–NCT, and (2) at higher heating rates (108C/min) individual components
crystallize, then melt and the stable cocrystalline phase nucleates and grows from the
melt. Isothermal studies above theTg of the amorphous equimolar phase also confirm the
nucleation of a metastable cocrystalline phase from the amorphous state followed by a
solid phase mediated transformation to the stable cocrystalline phase. Cocrystallization
kinetics were measured by image analysis and by thermal analysis from small samples
and are described by the Avrami–Erofeev model. These findings have important
implications for the use of amorphous phases in the discovery of cocrystals and to
determine the propensity of cocrystallization from process-induced amorphization.
 2007Wiley-Liss, Inc. and theAmericanPharmacists Association J PharmSci 96:1147–1158, 2007
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INTRODUCTION
Understanding the thermodynamic, kinetic, and
molecular phenomena that determine crystalliza-
tion events has been of great importance in the
pharmaceutical area to meet the safety and
efficacy requirements of pharmaceutical pro-
ducts.1–6 The success of applying fundamental
concepts has been demonstrated in directing
crystallization outcomes from liquid phases,7–9
and in preventing crystallization from solid amor-
phous phases.2–4,6,10,11 Among the repertoire of
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noncovalent interactions inherent to molecular
recognition, hydrogen bonds because of their
strength and directionality have been shown to
drive molecular associations that lead to crystal-
line or noncrystalline solids.11–14 Hydrogen-bond
motifs revealed by molecular arrangements
in single component and multiple component
crystals (cocrystals)15–18 have also contributed
to directed nucleation of polymorphs, solvates,
and cocrystals.8,9,14,19–23 Hydrogen bonds are
thus a common feature for the formation of
molecular complexes and networks that facilitate
or prevent crystallization.
Cocrystals aremultiple component crystals that
often rely on hydrogen bonds between neutral
molecules. Therefore, cocrystallization requires
that molecular associations between different
components, or heteromers, be more favorable
than those between the same components, or
homomers.15,16 It is important to note that a
cocrystal is a single phase of multiple components
and not a mixture of single component crystalline
phases. Cocrystallization is attractive because it
enables the modification and engineering of
important physicochemical properties, such as
solubility, dissolution rate, bioavailability, hygro-
scopicity, morphology, compaction, and melting
point.14,18,19,24–27 While pharmaceutical cocrys-
tals have been discovered by liquid and solid-state
processes,18,27–29 the mechanisms and kinetics of
formation have received little attention.
Earlier reports from our laboratory show that
cocrystal formation from solution is explained by
solution chemistry models and that supersatura-
tion with respect to cocrystal is generated by
dissolving nonequivalent amounts of cocrystal
components.20,21 The mechanisms for sponta-
neous cocrystal formation in aqueous and organic
media have been described and applications to
cocrystallization methods have been presented.21
Cogrinding solid reactants has been an attrac-
tive method to screen for cocrystals and is a way to
circumvent the large number of experimental
variables involved in solution processes.15,16,30–33
Phase transformations induced by grinding or
milling have been thoroughly studied in the
pharmaceutical literature.34–38 These transfor-
mations are often accompanied by solid-state
disorder and include polymorphic transforma-
tions, proton transfer reactions, complexation,
and cocrystallization. We have recently demon-
strated that cocrystallization can proceed
during storage after mechanical activation of the
reactants and that the reaction is associated with
the propensity of crystalline reactants to
form disordered or amorphous phases during
mechanical stress.39,40 The present work is part
of a study to understand the factors that control
amorphous phase-mediated cocrystallization. Key
questions that will be addressed are whether
amorphous phases lead to cocrystal formation
and if there is a relation between temperature
and crystallization pathways.
The carbamazepine–nicotinamide cocrystal
(CBZ–NCT) with a 1:1 molar ratio was used as
a model system to study the crystallization
behavior above the glass transition temperature
of equimolar amorphous phases prepared by
melt quenching. The molecular arrangement
showing the hydrogen bond motifs between
these two components in the CBZ–NCT cocrystal
prepared from solvent or by room temperature
cogrinding18,20,21,39 is presented in Figure 1.
Crystallization pathways and kinetics were deter-
mined by studying the thermal behavior of
amorphous phases of reactants by using hot-
stage polarized microscopy (HSPM), hot-stage
Raman microscopy (HSRM), differential scanning




Carbamazepine monoclinic (CBZ(III), Tm¼
1788C) and nicotinamide (NCT(I), Tm¼ 1288C)
were purchased from Sigma (Milwaukee, WI) and
were used as received. CBZ–NCT cocrystals
(CBZ–NCT(I)) were prepared from solution by
the methods described by Nehm et al.20,21
Amorphous equimolar phaseswere prepared by
quenching the melted cocrystal of CBZ–NCT(I)
in situ in DSC pans and on a controlled tempera-
ture microscope stage as described in the sections
below. Since the cocrystal has a melting tem-
perature of 1588C,24,25 about 208C lower than that
of the monoclinic form of CBZ (III), it allows for




DSC was performed on a TA Instruments (New
Castle, DE) Q1000 DSC with refrigerated cooling
system. The DSC was calibrated for temperature
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and cell constants using indium. The samples
were continuously purged with N2 at 50 mL/min.
DSC data were collected in triplicate, nonisother-
mally at ramping rates between 0.5 and 308C/min,
and isothermally at temperatures of 56, 61, and
668C. Samples of 2–7 mg were weighed and
sealed in crimped aluminum pans. Amorphous
samples were prepared in situ by heating CBZ–
NCT(I) just past the 1588C melt and cooling
at 208C/min down to 308C. Temperatures
reported are onset temperatures unless otherwise
specified.
Hot-Stage Polarized Optical Microscopy
HSPM studies were conducted on a Leica DMPL
polarizing optical microscope (Leica Micro-
systems Wetzlar GmbH, Wetzlar, Germany) and
a Linkham THMS600 hot stage with liquid
nitrogen cooling (Linkham Scientific Instruments
Ltd, Surry, England). A full wave compensator
plate was used with cross polarizing filters to
enhance the optical features of some of the
samples, while collection without the compen-
sator plate was performed for crystallization
kinetics data. Images were collected with a
Spot Insight FireWire 4 Megasample Color
Mosaic camera controlled with Spot software
(Diagnostics Inc, Sterling Heights, MI).
Amorphous samples for HSPM studies were
prepared in situ by placing 1–3mgofCBZ–NCT(I)
between two borosilicate glass windows in the hot
stage. The samples were then subjected to a
temperature program that would allow complete
melting prior to quenching to 208C at 1258C/
min. The resulting amorphous material was
then either heated to a selected temperature
for isothermal studies or heated through the melt
at a specified heating rate for nonisothermal
studies.
X-Ray Powder Diffraction
XRPD patterns were collected on an X-ray
diffractometer (Rigaku Ultima-plus, Tokyo,
Japan) with Cu K-alpha radiation operating at
30 kV and 15 mA. Samples were scanned from 38
to 508 2-Y at a step size of 0.048 2-Y and at 2.4 s
per step.
Hot-Stage Raman Microscopy
Raman spectroscopy was carried out using a
Kaiser Optical Systems (Ann Arbor, MI) HoloLab
series 5000 Raman spectrometer equipped with a
300 mW external cavity stabilized diode laser
operating at 785 nm. A Leica DMLP microscope
was used in conjunction with a Mettler-Toledo
(Columbus, OH) F82 hot stage for temperature
control. Raman spectra were collected in back
scattering geometry using sample sizes of 1–3mg.
Amorphous samples were prepared between a
polished aluminum base and a quartz cover slip
in the hot stage using the method described in
the HSPM section. The spectra had a 4 cm1
Figure 1. Hydrogen bonds between NH and C–O of amide groups in the
carbamazepine–nicotinamide cocrystal CBZ–NCT (I).
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resolution and were collected between 100 and
3200 cm1.
Image-Based Crystallization Analysis
Crystallization kinetic data from the amorphous
films of CBZ and NCT were obtained by analyzing
images collected from HSPM in a manner derived
from methods based on total transmitted sample
intensity.41 The microscope was set up with the
polarizer and analyzer completely crossed with-
out the use of the full-wave compensator. This
configuration allowed the amorphous regions
to appear black. A 10 objective was used to
maximize the observed area within the constraint
of the light path of the hot stage. The recorded
images represented a 1.5 1.5 mm2 area. Initial
light intensities of the amorphous materials were
adjusted to be just above the threshold of detec-
tion on the CCD camera to be sure changes in
transmission could be recorded, even at the lowest
levels. Images were collected at time intervals,
typically every 15, 30, or 60 s.
The sequence of images was analyzed with
ImageJ42 software by generating a histogram of
pixel intensities for each image in the sequence.
The initial image acted as the calibration, setting
the initial intensity range that was considered to
be black. The black pixel count from each image
was then used to calculate the amorphous content.
Since anything that was not black was considered
crystalline, the crystal fractionwas computed from
the following equation:
t ¼ 1
00black00 pixels at time ¼ t
00black00 pixels at time ¼ 0
ð1Þ
A nonlinear least-squares fit of a suitable crystal-
lization model to the data resulted in kinetic and
mechanistic information.
DSC-Based Crystallization Analysis
Isothermal experiments carried out on the DSC
exhibited time-dependent exothermic events due
to crystallization. These events were analyzed
and kinetic parameters were determined by
computing a running integral across the event
by a method similar to that described by Zhou
et al.3 The crystal fraction, , was then obtained
by normalizing the integral. Models were then
evaluated based on best fit to the data to obtain
kinetic information.
Nonisothermal experiments were also per-
formed to compare thermal characteristics under
differing conditions. These experiments utilized












where  is the heating rate, Tc is the peak
crystallization temperature, A is the frequency
factor, R is the gas constant, and Ea is the
activation energy. From the plot of 1/Tc versus.
ln(/Tc
2), the slope provides Ea, and the intercept
provides A.
RESULTS AND DISCUSSION
Thermal analysis of the CBZ–NCT (I) cocrystal
prepared from liquid solutions shows a single
endothermic event at 1588C (Fig. 2a). This event
is due to the melt of the cocrystal. Amorphous
equimolar phases of CBZ and NCT were prepared
in situ by quenching the melt of CBZ–NCT(I)
cocrystal to ensure a uniform distribution of
components. Cooling rates as slow as 208C/min
resulted in the formation of an amorphous phase
as indicated by the lack of birefringence on
Figure 2. DSC results showing thermal behavior
during heating (a) cocrystal prepared from solution
CBZ–NCT(I), (b) amorphous equimolar phase of CBZ
and NCT at 108C/min, and (c) amorphous equimolar
phase of CBZ and NCT at 38C/min. Dashed lines are
expanded views for clarity.
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polarized light microscopy studies and the glass
transition temperature shown in Figure 2b and c.
Thermal analysis of these amorphous phases at
heating rates of 3 and 108C/min shows a glass
transition at 19–228C followed by different
events. At a heating rate of 108C/min the thermo-
gram in Figure 2b shows an exotherm at 878C, an
endotherm at 125–1288C followed immediately
by an exotherm, and finally the endothermic melt
of the cocrystal CBZ–NCT(I) at 1588C. The
thermogram in Figure 2c at the lower heating
rate of 38C/min exhibits different behavior with
two exothermic events at 678C and 958C followed
by the 1588C melt of the cocrystal.
Crystallization from the amorphous phase of
CBZ and NCT was also investigated by HSPM
under isothermal conditions at 41, 61, 81, and
958C. Amorphous materials were prepared in situ
on thehot stage and the sampleswere examined by
image analysis. The photomicrographs in Figure 3
were collected during these experiments and show
various stages of crystallization from the amor-
phous phase. A crystallization event from
the amorphous state is first observed by the
birefringent phase that nucleates and grows as
shown in Figure 3 (upper left and right) at 418C
and 618C. This initial phase subsequently trans-
forms to another form as shown in Figure 3 (lower
left and right) at 818C and 95 8C. The transforma-
tion front, noted by the arrows in Figure 3,
continued tomove across the viewable region until
the entire sample was transformed. A single melt
was observed from this transformed material at
158–1628C upon subsequent heating at 108C/min.
The crystals formed at 41 and 618C did not show
any transformation under isothermal conditions
within 24 and 3 h, respectively, but did exhibit a
transformation similar to that observed at 81 and
958C upon heating at 108C/min that was then
followed by a single melt at 158–1628C.
In order to gain more information about
the phase transformations, Raman microscopy
Figure 3. Photomicrographs of isothermal crystallization from amorphous equimolar
phase of CBZ and NCT at 418C/16 h (upper left), 618C/90 min (upper right), 818C/30 min
(lower left), and 958C/30 min (lower right). Note the solid–solid transformation front
indicated by the arrows in the 81 and 958C images.
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studies were carried out isothermally at 618C on
the hot stage with similar configuration to that
used in the HSPM studies. As shown in Figure 4
the Raman spectrum of the phase initially crystal-
lized is different from that of the single component
crystals CBZ(III) and NCT(I). The shift in the
spectral peaks from 1038 cm1 for the amorphous
phase to 1042 cm1 for this solid phase and back to
1036 cm1 for CBZ–NCT(I) precludes the possibi-
lity that this initial solid phase was a mixture of
amorphous phase and CBZ–NCT(I) cocrystal.
This indicates that the initial phase is different
from CBZ–NCT(I) and the amorphous phase of
CBZ and NCT.
The time dependence of XRPD patterns show-
ing crystallization from the amorphous phase of
CBZ andNCT at 618C is presented in Figure 5. For
reference, the XRPD pattern for CBZ–NCT(I)
prepared from solution is also presented. The
patterns in the early stages of the process show
broad peaks of low intensities indicating a par-
tially crystalline sample. There are also peaks at
5.68 and 8.78 2Y that do not appear in the XRPD
pattern of the reference cocrystal of CBZ–NCT (I).
Clear trends can be observed in the development of
peaks during the experiment that suggest an
intermediate phase, which we are referring to as
CBZ–NCT(II), that precedes the formation of the
stable phase of the cocrystal CBZ–NCT(I).
The thermal events associated with the transi-
tion fromCBZ–NCT form II to form I are shown in
Figure 6. An exothermic transition is observed at
83–908C with an enthalpy of 8.1–11.1 J/g when
CBZ–NCT(II) is heated at a rate of 3–208C/min,
respectively. This indicates that there is a mono-
tropic relationship between these forms.44 Studies
Figure 4. Raman spectra comparing single compo-
nent crystals, cocrystals, and amorphous equimolar
phase of CBZ and NCT.
Figure 5. XRPD diffraction patterns showing the
time course for crystallization from the amorphous
phase of CBZ andNCT at 618C. For reference, the XRPD
pattern for CBZ–NCT(I) prepared from solution is also
included.
Figure 6. DSC results showing the thermal behavior
of CBZ–NCT (II) indicating the exothermic transition to
CBZ–NCT(I) followed by the melt of form (I).
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to confirm the structure of this newphase continue
in our laboratory.
Two different cocrystallization pathways from
the amorphous phase were identified under high
and low heating rates. Figure 7 shows the DSC
thermogram and photomicrographs from HSPM
for the cocrystallization pathway observed at
108C/min. This is characterized by the crystal-
lization of single component phases of CBZ and
NCT at 878C. These events were followed by the
melting ofNCT(I) at 1258C, dissolution of CBZ into
this melt, crystallization of CBZ–NCT(I), and the
melting ofCBZ–NCT(I) at 1588C.A slowerheating
rate of 38C/min resulted in a different pathway as
shown in Figure 8. The crystallization of CBZ–
NCT(II) at 728C is followed by an exothermic
transition to CBZ–NCT(I) at 878C and the melt of
CBZ–NCT(I) at 1588C.
The kinetics of isothermal crystallization of
CBZ–NCT (II) from the amorphous phase
using the data from the automated HSPMmethod
(n¼ 3) are presented in Figure 9. Results at 818C
and 958C are highly reproducible, however, a
wide spread in the data was observed at 618C.
This is a result of the slower crystallization
rates at 618C, the intrinsic distribution of induc-
tion times for nucleation, and the limited field of
view of the microscope relative to the total sample
area.
The exothermic events corresponding to crys-
tallization of CBZ–NCT(II) from the amorphous
phase at 56, 61, and 668C measured during
isothermal DSC studies are presented in
Figure 10. The crystallization results from the
618C study are plotted along with the HSPM-
derived data for comparison in Figure 11. The
superior reproducibility of the DSC kinetic data is
shown here and is the reason for using DSC data
for quantitative crystallization analysis.Note here
that this is not a reason to abandon HSPM
methodology for kinetics investigation, however,
since HSPM can provide important qualitative
information that simply cannot be captured or
interpreted from DSC only.
The automated HSPM method for monitoring
crystallization was used in this study and com-
plemented well the DSC analysis. In fact, HSPM
provided the first evidence of a phase transition
after the initial crystallization of CBZ–NCT(II).
Figure 12 shows a composite of approximately 150
individual images captured from one completely
crystallized sample, 16 mm in diameter. The
accompanying graphic depicts the nucleation
centers with the small black square indicating
the relative size of the field of view to the entire
sample. Visual inspection reveals that many
random samples would be required to obtain a
representative average from thedistribution of the
997 nucleation sites in this case. Therefore, the
combination of both macro and micro methods of
analysis provides mechanistic and kinetic infor-
mation that is representative of the system under
consideration.
The fraction crystallized as a function of time
based on DSC studies at 56, 61, and 668C is shown
in Figure 13. An r2 analysis of least-squares fit of
various models (see Table 1) showed that the
Avrami–Erofeev model with an exponent value of
Figure 7. DSC and HSPM results during nonisothermal crystallization studies of
amorphous phase of CBZ and NCT at 108C/min.
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3 best describes the results. The Avrami–Erofeev
model used was:
 ¼ 1 e ktð Þ
n
ð3Þ
where k is the rate constant and n is the exponent.
Activation energy, Ea, for the crystallization of
CBZ–NCT (II) was determined to be 61 kJ/mol
over the temperature range of 56–668C using
the rate constants evaluated from the Avrami–
Eerofev model in an Arrhenius analysis.
A Kissinger plot was constructed to further
investigate crystallization kinetics from noni-
sothermal DSC with ramp rates between 0.5 and
258C/min and is presented in Figure 14. This
plot shows two distinct, linear regions that
correlate with the crystallization of CBZ–NCT(II)
(steeper slope) or the crystallization of individual
components. The transition between these two
pathways occurs at 9.78C/min heating rate. From
Figure 10. Isothermal DSC thermograms during
crystallization from the amorphous phase at 56, 61,
and 668C.
Figure 9. Isothermal HSPM-derived crystallization
data at 61, 81, and 958C.
Figure 8. DSC andHSPM results during nonisother-
mal crystallization studies of amorphous phase of CBZ
and NCT at 38C/min.
Figure 11. Comparison of crystallization kinetics
measured in DSC and HSPM at 618C.
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the slopes, the Ea was calculated to be 37.6 kJ/mol
and 83.4 kJ/mol for the crystallization of CBZ and
NCT individually and for the crystallization of
CBZ–NCT(II), respectively.
The transformation from the amorphous to
cocrystalline form (II) to form (I) was studied
under isothermal conditions at 618C by hot stage
Raman microscopy and the results of triplicate
experiments are shown in Figure 15. The peak
intensity at 1040 cm1 was used to follow
the conversion because there are significant
differences near this peak position between the
three forms (amorphous-1038 cm1, CBZ–
NCT(II)-1042 cm1, CBZ–NCT(I)-1036 cm1).
The peak intensity at 1040 cm1 was normalized
using the consistent peak at 1306 cm1. These
results are in good agreement with those of DSC
and HSPM studies. The time scale for the initial
crystallization of CBZ–NCT(II) was the same as
that observed by DSC and HSPM. The transfor-
mation rate for CBZ–NCT (II) to (I) was constant
in these experiments as indicated by the parallel
trends in the decrease of peak ratios with time.
The induction times for nucleation of form (I),
however, varied noticeably. This distribution
of induction times is inherent to the small
sampling area and conditions where nucleation
events are widely distributed as observed in
HSPM studies.
Figure 12. Composite image of crystallized CBZ–NCT(II) from the amorphous phase.
Black square represents 1.5 1.5mm2 viewing area available for HSPM. The graphic on
the right shows the distribution of 997 nucleation points.
Figure 13. DSC derived crystallization data from
isothermal studies at 56, 61, and 668C.
Table 1. Evaluation of Kinetic Models to Describe
Isothermal Cocrystallization from Amorphous Equimolar
Phase of CBZ and NCT Determined by DSC
Model/Mechanism r2
Avrami–Erofeev n¼ 3 0.9894
One-dimensional diffusion 0.9074
Two-dimensional diffusion 0.9093





Random nucleation (Prout–Tompkins) 0.9581
Power law (n¼ 1/2) 0.8790
Power law (n¼ 1/3) 0.8410




Two-dimensional phase boundary reaction 0.9531
Three-dimensional phase boundary reaction 0.9525
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CONCLUSIONS
The results presented here show that amorphous
phases generate cocrystals and that thermal
history affects crystallization pathways in signifi-
cant ways. Studies of amorphous films and small
samples of equimolar composition of carbamaze-
pine and nicotinamide were carried out under
nonisothermal and isothermal conditions. Ther-
mal microscopy (polarized light microscopy and
Raman microscopy), thermal analysis (DSC), and
XPRD methods were valuable tools in identifying
the crystallization behavior and kinetics. During
nonisothermal studies two different pathways
to cocrystal formation from the amorphous
phase were identified: (1) at low heating rates a
metastable cocrystalline phase initially nucleates
and transforms to the more stable cocrystalline
phase of CBZ–NCT, and (2) at higher heating
rates individual components crystallize, then
melt and the stable cocrystalline phase
nucleates and grows from the melt. Isothermal
studies above the Tg of the amorphous
equimolar phase also confirm the nucleation of a
metastable cocrystalline phase and a solid phase
mediated transformation to the stable cocrystal-
line phase. Cocrystallization kinetics were mea-
sured by image analysis and by thermal analysis
from small samples and are described by the
Avrami–Erofeev model. These findings have
important implications for the use of amorphous
phases for the discovery of cocrystals and to
identify the propensity of cocrystallization from
amorphous phases induced by pharmaceutical
processes.
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